The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

As of Thursday, January 08, Corvus Pharmaceuticals, Inc.’s CRVS share price has dipped by 6.45%, which has investors ...

EXCLUSIVE: For centuries, people across the world have turned to weird and wonderful cures in the name of healing.

Clarivate Plc , a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact ...

Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient careLONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. | Two investigational cardiometabolic drugs from Eli ...

A multiyear community asthma program on the Navajo Nation increased asthma-related care and awareness among families, even as ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

The XGBoost model predicts hyperglycemia risk in psoriasis patients with high accuracy, achieving an AUC of 0.821 in the training set. A web-based calculator was developed to facilitate personalized ...

Among adolescents with asthma and overweight or obesity, the relative risk for acute asthma exacerbations was significantly reduced with GLP-1 receptor agonist use vs. nonpharmacological weight ...

Pain-sensing neurons in the gut kindle inflammatory immune responses that cause allergies and asthma, according to a new ...